These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 25082276)

  • 1. MET inhibitors start on road to recovery.
    Garber K
    Nat Rev Drug Discov; 2014 Aug; 13(8):563-5. PubMed ID: 25082276
    [No Abstract]   [Full Text] [Related]  

  • 2. c-Met inhibition.
    Salgia R
    Clin Adv Hematol Oncol; 2006 Nov; 4(11):823-4. PubMed ID: 17143251
    [No Abstract]   [Full Text] [Related]  

  • 3. MET receptor tyrosine kinase.
    Faoro L; Cervantes GM; El-Hashani E; Salgia R
    J Thorac Oncol; 2009 Nov; 4(11 Suppl 3):S1064-5. PubMed ID: 19861919
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Developing biomarkers to predict benefit from HGF/MET pathway inhibitors.
    Koeppen H; Rost S; Yauch RL
    J Pathol; 2014 Jan; 232(2):210-8. PubMed ID: 24105670
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EGFR Status in Mesothelioma: Possible Implications for the Efficacy of Anti-EGFR and Anti-MET Therapies.
    Salvi S; Varesano S; Boccardo S; Ravetti JL; Canessa PA; Pistillo MP; Ferro P; Fedeli F; Roncella S
    J Thorac Oncol; 2016 Jun; 11(6):e78-80. PubMed ID: 27211582
    [No Abstract]   [Full Text] [Related]  

  • 6. MET as a drug target.
    Salgia R
    Clin Adv Hematol Oncol; 2015 Jun; 13(6):351-3. PubMed ID: 26352889
    [No Abstract]   [Full Text] [Related]  

  • 7. Targeting the MET gene for the treatment of non-small-cell lung cancer.
    Gelsomino F; Facchinetti F; Haspinger ER; Garassino MC; Trusolino L; De Braud F; Tiseo M
    Crit Rev Oncol Hematol; 2014 Feb; 89(2):284-99. PubMed ID: 24355409
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases.
    Rodig SJ; Shapiro GI
    Curr Opin Investig Drugs; 2010 Dec; 11(12):1477-90. PubMed ID: 21154129
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of novel 2-aminopyridine-3-carboxamides as c-Met kinase inhibitors.
    Zhang D; Ai J; Liang Z; Li C; Peng X; Ji Y; Jiang H; Geng M; Luo C; Liu H
    Bioorg Med Chem; 2012 Sep; 20(17):5169-80. PubMed ID: 22863529
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ARQ-197, an oral small-molecule inhibitor of c-Met for the treatment of solid tumors.
    Bagai R; Fan W; Ma PC
    IDrugs; 2010 Jun; 13(6):404-14. PubMed ID: 20506063
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery and optimization of a potent and selective triazolopyridinone series of c-Met inhibitors.
    Bode CM; Boezio AA; Albrecht BK; Bellon SF; Berry L; Broome MA; Choquette D; Dussault I; Lewis RT; Lin MH; Rex K; Whittington DA; Yang Y; Harmange JC
    Bioorg Med Chem Lett; 2012 Jun; 22(12):4089-93. PubMed ID: 22595176
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progress in cancer therapy targeting c-Met signaling pathway.
    Jung KH; Park BH; Hong SS
    Arch Pharm Res; 2012 Mar; 35(4):595-604. PubMed ID: 22553051
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [A simple view on lung cancer biology: the MET pathway].
    Ruppert AM; Beau-Faller M; Belmont L; Lavolé A; Gounant V; Cadranel J; Wislez M
    Rev Mal Respir; 2011 Dec; 28(10):1241-9. PubMed ID: 22152933
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug development of MET inhibitors: targeting oncogene addiction and expedience.
    Comoglio PM; Giordano S; Trusolino L
    Nat Rev Drug Discov; 2008 Jun; 7(6):504-16. PubMed ID: 18511928
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting the Met pathway in lung cancer.
    Belalcazar A; Azaña D; Perez CA; Raez LE; Santos ES
    Expert Rev Anticancer Ther; 2012 Apr; 12(4):519-28. PubMed ID: 22500688
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined SVM-based and docking-based virtual screening for retrieving novel inhibitors of c-Met.
    Xie QQ; Zhong L; Pan YL; Wang XY; Zhou JP; Di-Wu L; Huang Q; Wang YL; Yang LL; Xie HZ; Yang SY
    Eur J Med Chem; 2011 Sep; 46(9):3675-80. PubMed ID: 21641696
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of a novel series of quinoxalines as inhibitors of c-Met kinase.
    Porter J; Lumb S; Lecomte F; Reuberson J; Foley A; Calmiano M; le Riche K; Edwards H; Delgado J; Franklin RJ; Gascon-Simorte JM; Maloney A; Meier C; Batchelor M
    Bioorg Med Chem Lett; 2009 Jan; 19(2):397-400. PubMed ID: 19059779
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic targeting of the receptor tyrosine kinase Met.
    Sattler M; Ma PC; Salgia R
    Cancer Treat Res; 2004; 119():121-38. PubMed ID: 15164876
    [No Abstract]   [Full Text] [Related]  

  • 19. c-MET kinase inhibitors: a patent review (2011 - 2013).
    Zhu K; Kong X; Zhao D; Liang Z; Luo C
    Expert Opin Ther Pat; 2014 Feb; 24(2):217-30. PubMed ID: 24266843
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of 4-azaindoles as novel inhibitors of c-Met kinase.
    Porter J; Lumb S; Franklin RJ; Gascon-Simorte JM; Calmiano M; Riche KL; Lallemand B; Keyaerts J; Edwards H; Maloney A; Delgado J; King L; Foley A; Lecomte F; Reuberson J; Meier C; Batchelor M
    Bioorg Med Chem Lett; 2009 May; 19(10):2780-4. PubMed ID: 19369077
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.